Jennifer J Schlezinger


Affiliation: Boston University
Country: USA


  1. request reprint
    Schlezinger J, Jensen B, Mann K, Ryu H, Sherr D. Peroxisome proliferator-activated receptor gamma-mediated NF-kappa B activation and apoptosis in pre-B cells. J Immunol. 2002;169:6831-41 pubmed
    ..These results have implications for the nominal role of the PPARgamma in B cell development and for the use of PPARgamma agonists as immunomodulatory therapeutics. ..
  2. Kim S, Li A, Monti S, Schlezinger J. Tributyltin induces a transcriptional response without a brite adipocyte signature in adipocyte models. Arch Toxicol. 2018;92:2859-2874 pubmed publisher
    ..Furthermore, rosiglitazone, but not TBT, induced mitochondrial biogenesis and respiration. This study is the first to show that an environmental PPAR? ligand has a limited capacity to induce health-promoting activities of PPAR?. ..
  3. request reprint
    Schlezinger J, Emberley J, Bissonnette S, Sherr D. An L-tyrosine derivative and PPARgamma agonist, GW7845, activates a multifaceted caspase cascade in bone marrow B cells. Toxicol Sci. 2007;98:125-36 pubmed
    ..These data support the hypothesis that pharmacologic concentrations of PPARgamma agonists induce an intrinsic apoptotic pathway that is driven in normal bone marrow B cells by multiple amplification loops. ..
  4. request reprint
    Schlezinger J, Howard G, Hurst C, Emberley J, Waxman D, Webster T, et al. Environmental and endogenous peroxisome proliferator-activated receptor gamma agonists induce bone marrow B cell growth arrest and apoptosis: interactions between mono(2-ethylhexyl)phthalate, 9-cis-retinoic acid, and 15-deoxy-Delta12,14-prostaglandin. J Immunol. 2004;173:3165-77 pubmed
    ..These data demonstrate that environmental phthalates can cooperate with an endogenous ligand, 15d-PGJ(2), to inhibit proliferation of and induce apoptosis in developing bone marrow B cells, potentially via PPARgamma activation. ..
  5. Schlezinger J, Bernard P, Haas A, Grandjean P, Weihe P, Sherr D. Direct assessment of cumulative aryl hydrocarbon receptor agonist activity in sera from experimentally exposed mice and environmentally exposed humans. Environ Health Perspect. 2010;118:693-8 pubmed publisher
    ..Significant levels of AhR agonist activity in commercial sera and in Faroe Islander sera, compared with that from experimentally exposed mice, suggest human exposures that are biologically relevant in both populations. ..
  6. Watt J, Schlezinger J. Structurally-diverse, PPARγ-activating environmental toxicants induce adipogenesis and suppress osteogenesis in bone marrow mesenchymal stromal cells. Toxicology. 2015;331:66-77 pubmed publisher
  7. Watt J, Webster T, Schlezinger J. Generalized Concentration Addition Modeling Predicts Mixture Effects of Environmental PPARγ Agonists. Toxicol Sci. 2016;153:18-27 pubmed publisher
    ..These experiments support the implementation of GCA in mixtures analysis with endocrine disrupting compounds and establish PPARγ as an important target for further studies of chemical mixtures. ..
  8. Narasimhan S, Stanford Zulick E, Novikov O, Parks A, Schlezinger J, Wang Z, et al. Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor. Int J Mol Sci. 2018;19: pubmed publisher
    ..These data demonstrate the complexity of modulating AHR activity in cancer while suggesting that AHR inhibitors, and, under some circumstances, AHR agonists, may be useful as cancer therapeutics. ..